BeiGene | Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

⟵ Back to Search Results

Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

Beigene Study ID

BGB-dinutuximab beta-101

ClinicalTrials.gov ID

NCT05373901

China Drug Trials ID

CTR20221154

Study Overview

Sex: All

Age: 12 Months / N/A

No Study Documents

Study Overview

Sex: All

Age: 12 Months / N/A

No Study Documents